<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/17/halozyme-therapeutics-inc-nasdaqhalo-expected-to-post-fy2019-earnings-of-0-43-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-17T05:56:55+00:00"/>
    <meta property="og:title" content="Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Post FY2019 Earnings of ($0.43) Per Share"/>
    <meta property="og:description" content="Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Cantor Fitzgerald reduced their FY2019 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($0.43) per share for the year, down from their prior forecast […]"/>
  </head>
  <body>
    <article>
      <h1>Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Post FY2019 Earnings of ($0.43) Per Share</h1>
      <address><time datetime="2019-11-17T05:56:55+00:00">17 Nov 2019, 05:56</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/halozyme-therapeutic-logo.gif"/>
      </figure>
      <p>Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Cantor Fitzgerald reduced their FY2019 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($0.43) per share for the year, down from their prior forecast of ($0.29).</p>
      <p>Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $46.20 million during the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The firm’s revenue was up 80.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.19) EPS.</p>
      <p>Other analysts have also issued reports about the company. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=HALO">ValuEngine</a> lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. JPMorgan Chase &amp; Co. raised their target price on Halozyme Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday. BMO Capital Markets raised their target price on Halozyme Therapeutics from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday. Barclays raised Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and decreased their target price for the stock from $17.00 to $16.00 in a research report on Tuesday, November 5th. Finally, BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $20.33.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/HALO/earnings/">NASDAQ:HALO</a> opened at $18.91 on Friday. The business’s 50 day simple moving average is $15.86 and its two-hundred day simple moving average is $16.17. The firm has a market cap of $2.71 billion, a P/E ratio of -33.77 and a beta of 1.78. Halozyme Therapeutics has a 52-week low of $13.24 and a 52-week high of $19.05. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.57 and a current ratio of 3.17.</p>
      <p>A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Halozyme Therapeutics by 8.0% in the second quarter. BlackRock Inc. now owns 12,625,128 shares of the biopharmaceutical company’s stock worth $216,900,000 after buying an additional 929,980 shares during the last quarter. Invesco Ltd. increased its position in Halozyme Therapeutics by 28.2% in the second quarter. Invesco Ltd. now owns 5,387,409 shares of the biopharmaceutical company’s stock worth $92,555,000 after buying an additional 1,183,551 shares during the last quarter. William Blair Investment Management LLC increased its position in Halozyme Therapeutics by 774.0% in the second quarter. William Blair Investment Management LLC now owns 3,538,927 shares of the biopharmaceutical company’s stock worth $60,799,000 after buying an additional 3,134,003 shares during the last quarter. FMR LLC increased its position in Halozyme Therapeutics by 5.0% in the first quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock worth $43,238,000 after buying an additional 127,379 shares during the last quarter. Finally, Northern Trust Corp increased its position in Halozyme Therapeutics by 0.5% in the second quarter. Northern Trust Corp now owns 1,790,475 shares of the biopharmaceutical company’s stock worth $30,760,000 after buying an additional 8,377 shares during the last quarter. 84.35% of the stock is owned by institutional investors and hedge funds.</p>
      <p>
        <b>Halozyme Therapeutics Company Profile</b>
      </p>
      <p>Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/difference-between-common-shares-and-convertible-shares/">What is the Difference Between Common Shares and Convertible Shares?</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=HALO"/>
      </figure>
    </article>
  </body>
</html>